CN112585132B - 蛋白酶体活性增强化合物 - Google Patents

蛋白酶体活性增强化合物 Download PDF

Info

Publication number
CN112585132B
CN112585132B CN201980055152.2A CN201980055152A CN112585132B CN 112585132 B CN112585132 B CN 112585132B CN 201980055152 A CN201980055152 A CN 201980055152A CN 112585132 B CN112585132 B CN 112585132B
Authority
CN
China
Prior art keywords
optionally substituted
group
alkyl
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980055152.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112585132A (zh
Inventor
M·卡伦
C·M·巴斯托斯
D·帕克斯
B·穆诺茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umaniti
Original Assignee
Umaniti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umaniti filed Critical Umaniti
Publication of CN112585132A publication Critical patent/CN112585132A/zh
Application granted granted Critical
Publication of CN112585132B publication Critical patent/CN112585132B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980055152.2A 2018-06-27 2019-06-27 蛋白酶体活性增强化合物 Active CN112585132B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690563P 2018-06-27 2018-06-27
US201862690565P 2018-06-27 2018-06-27
US62/690,565 2018-06-27
US62/690,563 2018-06-27
PCT/US2019/039600 WO2020006296A1 (en) 2018-06-27 2019-06-27 Proteasome activity enhancing compounds

Publications (2)

Publication Number Publication Date
CN112585132A CN112585132A (zh) 2021-03-30
CN112585132B true CN112585132B (zh) 2025-02-28

Family

ID=67439356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055152.2A Active CN112585132B (zh) 2018-06-27 2019-06-27 蛋白酶体活性增强化合物

Country Status (17)

Country Link
US (2) US11560385B2 (https=)
EP (1) EP3814338A1 (https=)
JP (2) JP7561632B2 (https=)
KR (1) KR20210024588A (https=)
CN (1) CN112585132B (https=)
AU (1) AU2019295765B2 (https=)
BR (2) BR112020026580A2 (https=)
CA (1) CA3103954A1 (https=)
CL (1) CL2020003380A1 (https=)
CR (1) CR20200652A (https=)
IL (1) IL279698A (https=)
MA (1) MA53014A (https=)
MX (1) MX2020014082A (https=)
PE (1) PE20211804A1 (https=)
PH (1) PH12020552261A1 (https=)
SG (1) SG11202013026WA (https=)
WO (1) WO2020006296A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
CN111423353B (zh) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 多取代n-芳基吡咯类化合物及其制备方法
CN112142642B (zh) * 2020-10-15 2022-03-04 华侨大学 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法
WO2023107597A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Bicyclic heteroaromatic amide compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094545A2 (en) * 2010-01-28 2011-08-04 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1142508A (en) 1966-04-27 1969-02-12 Whitefin Holding Sa Pyrrole derivatives
GB1154744A (en) 1966-05-17 1969-06-11 Whitefin Holding Sa Disubstituted Aminoethanols
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
CZ20002669A3 (cs) 1998-01-23 2001-11-14 National Jewish Medical And Research Center Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
EP1682504B1 (en) 2003-11-12 2012-12-26 Amicus Therapeutics Inc. Hydroxy piperidine derivatives to treat gaucher disease
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101541172A (zh) 2005-06-08 2009-09-23 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
PT1860101E (pt) 2006-05-24 2011-07-12 Amicus Therapeutics Inc Sal de tartrato da isofagomina e métodos de uso
JP5303458B2 (ja) 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
DK2707101T3 (da) * 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
US9849135B2 (en) * 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
FR3008977A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094545A2 (en) * 2010-01-28 2011-08-04 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2015073528A1 (en) * 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN REGISTRY.STN REGISTRY.2008,1-3. *

Also Published As

Publication number Publication date
US20230183256A1 (en) 2023-06-15
WO2020006296A1 (en) 2020-01-02
US20210115057A1 (en) 2021-04-22
US12319698B2 (en) 2025-06-03
EP3814338A1 (en) 2021-05-05
BR112020026580A2 (pt) 2021-03-23
SG11202013026WA (en) 2021-01-28
KR20210024588A (ko) 2021-03-05
PE20211804A1 (es) 2021-09-14
JP7561632B2 (ja) 2024-10-04
MA53014A (fr) 2021-05-05
BR122023023216A2 (pt) 2024-02-20
PH12020552261A1 (en) 2021-08-02
CN112585132A (zh) 2021-03-30
IL279698A (en) 2021-03-01
JP2021529792A (ja) 2021-11-04
US11560385B2 (en) 2023-01-24
CL2020003380A1 (es) 2021-05-14
CA3103954A1 (en) 2020-01-02
MX2020014082A (es) 2021-04-13
AU2019295765B2 (en) 2024-08-29
JP2024138260A (ja) 2024-10-08
AU2019295765A1 (en) 2021-01-21
CR20200652A (es) 2021-04-28

Similar Documents

Publication Publication Date Title
CN112585132B (zh) 蛋白酶体活性增强化合物
US8748412B2 (en) Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators
RU2682245C1 (ru) Индазольные ингибиторы сигнального пути wnt и их терапевтические применения
US20240150324A1 (en) 5-Membered Heteroaryl Carboxamide Compounds for Treatment of HBV
EP3939979A1 (en) Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
EP3331884B1 (en) Urea derivative or pharmacologically acceptable salt thereof
JP6657413B2 (ja) Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法
JP2009544625A (ja) Ｒｈｏキナーゼのベンゾチオフェン阻害剤
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
JP2020508996A (ja) リシルオキシダーゼのハロアリルアミンピラゾール誘導体阻害剤およびその使用
JP2023513373A (ja) Ｐ２ｘ３修飾薬
JP2022533147A (ja) 芳香族アミン類のａｒ及びｂｅｔを標的とするタンパク質分解キメラ化合物及び使用
WO2022166860A1 (zh) Pim激酶抑制剂
CN115403584A (zh) 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
JP2023524547A (ja) Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
US20250059189A1 (en) Pyridine derivatives and their use as sodium channel activators
CA3201608A1 (en) Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
WO2021107125A1 (ja) リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途
TW202342061A (zh) Ｌｏｎｐ１抑制劑、用途及方法
HK40050827A (en) Proteasome activity enhancing compounds
ES2892175T3 (es) Moduladores de los receptores NMDA, composiciones que los incluyen y uso de dichos compuestos en el tratamiento de enfermedades que implican al sistema nervioso central
HK40050827B (zh) 蛋白酶体活性增强化合物
HK40085749A (en) P2x3 modulators
HK40116639A (zh) 用於治疗弗里德希共济失调的化合物和方法
JP2023070167A (ja) Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050827

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts

Applicant after: Umaniti

Address before: Massachusetts

Applicant before: PROTEOSTASIS THERAPEUTICS, Inc.

GR01 Patent grant
GR01 Patent grant